Introducing Professor Kausik Ray

Professor Kausik RayProfessor Kausik Ray joined Imperial College as Professor of Public Heath, Department of Primary Care and Public Health, School of Public Health in Feb 2015. A clinical cardiologist by training Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham, his MD (2004) from the University of Sheffield, a postdoctoral fellowship at Harvard Medical School (2004-2005) an MPhil in epidemiology (2007) from the University of Cambridge and was Chair in Preventive Cardiology at St Georges University of London from 2010.

Professor Ray’s research interests focus on the prevention of cardiovascular disease using observational methods and intervention studies including large trials. Recently Professor Ray has established the first global registry of Familial Hypercholesterolaemia in conjunction with the European Atherosclerosis Society (EAS) called the FH studies collaboration (FHSC) and is PI for the TOGETHER study looking at cardiometabolic risk factors and clinical outcomes in approximately 250 000 people using electronic health records in London.

Globally a child is born every minute with familial hypercholesterolaemia (FH) the commonest autosomally dominant condition known to man with a prevalence of about 1:200- 1:250. This results in lifetime elevations in low density lipoprotein cholesterol (LDL-C) resulting in premature morbidity and mortality from vascular disease. This condition can be treated by screening and early treatment with statins and other lipid lowering therapies. At the European Atherosclerosis Society Congress 2015 in Glasgow (http://eas.org), Professor Ray will launch the EAS FHSC, a global registry to harness information on the detection, management and clinical consequences of current practice on clinical outcomes. The mission statement is outlined below and for full details of the FHSC activities please see http://www.eas-society.org/fhsc.aspx

“The mission of the EAS FHSC is to empower the medical & global community to seek change in their respective countries or organizations regarding how FH is detected and managed, with a view to promoting early diagnosis and more effective treatment of this condition. Through international collaboration of stakeholders we aim to generate large scale robust data on how FH is detected, managed and the clinical consequences of current practice on outcomes.”

One comment for “Introducing Professor Kausik Ray

  1. Robert Fishberg says:

    Dear Dr Ray,
    I was very excited about ypur presentation at the AHA this week. I have previously heard you speak at the atherosclerosis
    meeting in Amsterdam. I am presently an investigator with Sanofi in the Odyssey outcome trial, the DalGene trial and the Cascade FH Registry. I would be very interested in being involved with any phase 3 trial involving ALN-PCSSC.
    Thank you.
    Robert FIshberg MD FACC
    Atlantic Health System
    Overlook, NJ

Leave a Reply

Your email address will not be published. Required fields are marked *